The relationship between controllability, optimal testing resource allocation, and incubation-latent period mismatch as revealed by COVID-19

The severe shortfall in testing supplies during the initial phases of the COVID-19 pandemic and ensuing struggle to control disease spread have affirmed the need to plan rigorous optimized supply-constrained resource allocation strategies for the next inevitable novel disease epidemic. To address the challenge of optimizing limited resource usage in the face of complicated disease dynamics, we develop an integro partial differential equation disease model which incorporates realistic latent, incubation, and infectious period distributions along with limited testing supplies for identifying and quarantining infected individuals, and we analyze the influence of these elements on controllability and optimal resource allocation between two testing strategies, `clinical' targeting symptomatic individuals and `non-clinical' targeting non-symptomatic individuals, for reducing total infection sizes. We apply our model to not only the original, delta, and omicron COVID-19 variants, but also to generic diseases which have different offsets between latent and incubation period distributions which allow for or prevent varying degrees of presymptomatic transmission or preinfectiousness symptom onset. We find that factors which reduce controllability generally call for reduced levels of non-clinical testing, while the relationship between symptom onset, controllability, and optimal strategies is complicated. Although greater degrees of presymptomatic transmission reduce disease controllability, they may enhance or reduce the role of non-clinical testing in optimal strategies depending on other disease factors like overall transmissibility and latent period length. Our model allows a spectrum of diseases to be compared under the same lens such that the lessons learned from COVID-19 can be adapted to resource constraints in the next emerging epidemic and analyzed for optimal strategies under a consistent mathematical framework.

[1]  Toshiyuki Shibata,et al.  Shorter Incubation Period among COVID-19 Cases with the BA.1 Omicron Variant , 2022, International journal of environmental research and public health.

[2]  E. Amirian Prioritizing COVID-19 test utilization during supply shortages in the late phase pandemic , 2022, Journal of Public Health Policy.

[3]  Reinhard Wallmann,et al.  Secondary Attack Rate, Transmission and Incubation Periods, and Serial Interval of SARS-CoV-2 Omicron Variant, Spain , 2022, Emerging infectious diseases.

[4]  Y. Liu,et al.  The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta , 2022, Journal of Travel Medicine.

[5]  E. Lau,et al.  Transmission dynamics and epidemiological characteristics of SARS-CoV-2 Delta variant infections in Guangdong, China, May to June 2021 , 2022, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[6]  V. Calvez,et al.  First cases of Omicron in France are exhibiting mild symptoms, November 2021–January 2022 , 2022, Infectious diseases now.

[7]  J. Calabrese,et al.  How optimal allocation of limited testing capacity changes epidemic dynamics , 2020, Journal of Theoretical Biology.

[8]  B. Abdalhamid,et al.  Investigation of a SARS-CoV-2 B.1.1.529 (Omicron) Variant Cluster — Nebraska, November–December 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[9]  T. Burki Omicron variant and booster COVID-19 vaccines , 2021, The Lancet Respiratory Medicine.

[10]  Jue Liu,et al.  Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals With Confirmed COVID-19 Diagnosis , 2021, JAMA network open.

[11]  Alberto Olivares,et al.  Optimal control-based vaccination and testing strategies for COVID-19 , 2021, Computer Methods and Programs in Biomedicine.

[12]  E. Lau,et al.  Estimating the latent period of coronavirus disease 2019 (COVID-19). , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  Y. Liu,et al.  The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus , 2021, Journal of travel medicine.

[14]  Kai Chen,et al.  Assessment of basic reproductive number for COVID-19 at global level , 2021, Medicine.

[15]  Josef A. Sifuentes,et al.  Social distancing and testing as optimal strategies against the spread of COVID-19 in the Rio Grande Valley of Texas , 2021, Infectious Disease Modelling.

[16]  M. Dawes,et al.  Determining the communicable period of SARS-CoV-2: A rapid review of the literature, March to September 2020 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[17]  Joshua Kiddy K. Asamoah,et al.  Sensitivity assessment and optimal economic evaluation of a new COVID-19 compartmental epidemic model with control interventions , 2021, Chaos, Solitons & Fractals.

[18]  Doménica Cevallos-Robalino,et al.  Statistical data driven approach of COVID-19 in Ecuador: R0 and Rt estimation via new method , 2021, Infectious Disease Modelling.

[19]  A. Rose COVID-19 economic impacts in perspective: A comparison to recent U.S. disasters , 2020, International Journal of Disaster Risk Reduction.

[20]  V. Lee,et al.  Infectivity of asymptomatic versus symptomatic COVID-19 , 2020, The Lancet.

[21]  L. D. Valdez,et al.  An epidemic model for COVID-19 transmission in Argentina: Exploration of the alternating quarantine and massive testing strategies , 2020, Mathematical Biosciences.

[22]  M. Cevik,et al.  SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis , 2020, The Lancet Microbe.

[23]  Yeung,et al.  The Incubation Period Distribution of Coronavirus Disease 2019: A Systematic Review and Meta-analysis , 2021 .

[24]  Matthew D Edwards,et al.  A holistic approach for suppression of COVID-19 spread in workplaces and universities , 2020, medRxiv.

[25]  J. A. Quesada,et al.  [Incubation period of COVID-19: A systematic review and meta-analysis]. , 2020, Revista clinica espanola.

[26]  D. Harrich,et al.  The unique features of SARS‐CoV‐2 transmission: Comparison with SARS‐CoV, MERS‐CoV and 2009 H1N1 pandemic influenza virus , 2020, Reviews in medical virology.

[27]  E. Clark,et al.  Why Contact Tracing Efforts Have Failed to Curb Coronavirus Disease 2019 (COVID-19) Transmission in Much of the United States , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  A. Gumel,et al.  Could masks curtail the post-lockdown resurgence of COVID-19 in the US? , 2020, Mathematical Biosciences.

[29]  Patricia Harrington,et al.  SARS-CoV-2 detection, viral load and infectivity over the course of an infection , 2020, Journal of Infection.

[30]  A. Broom,et al.  SARS-CoV-2: The viral shedding vs infectivity dilemma , 2020, Infection, Disease & Health.

[31]  Hadi Jahanshahi,et al.  Optimal policies for control of the novel coronavirus disease (COVID-19) outbreak , 2020, Chaos, Solitons & Fractals.

[32]  Vipin P. Veetil,et al.  The Economic Cost of COVID Lockdowns: An Out-of-Equilibrium Analysis , 2020, Economics of Disasters and Climate Change.

[33]  John T Brooks,et al.  Evidence Supporting Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic , 2020, Emerging infectious diseases.

[34]  Simon J. More,et al.  Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases , 2020, BMJ Open.

[35]  Luke O'Grady,et al.  Incubation period of COVID-19: a rapid systematic review and meta-analysis of observational research , 2020, BMJ Open.

[36]  D. Havlir,et al.  Asymptomatic Transmission, the Achilles’ Heel of Current Strategies to Control Covid-19 , 2020, The New England journal of medicine.

[37]  W. Padula Why Only Test Symptomatic Patients? Consider Random Screening for COVID-19 , 2020, Applied Health Economics and Health Policy.

[38]  C. Worby,et al.  Face mask use in the general population and optimal resource allocation during the COVID-19 pandemic , 2020, medRxiv.

[39]  E. Kostelich,et al.  To mask or not to mask: Modeling the potential for face mask use by the general public to curtail the COVID-19 pandemic , 2020, Infectious Disease Modelling.

[40]  K. Mandl,et al.  Early in the epidemic: impact of preprints on global discourse about COVID-19 transmissibility , 2020, The Lancet Global Health.

[41]  Malik Peiris,et al.  Viral dynamics in mild and severe cases of COVID-19 , 2020, The Lancet Infectious Diseases.

[42]  Hannah R. Meredith,et al.  The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application , 2020, Annals of Internal Medicine.

[43]  Don Klinkenberg,et al.  Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[44]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[45]  Paul J. Hurtado,et al.  Generalizations of the ‘Linear Chain Trick’: incorporating more flexible dwell time distributions into mean field ODE models , 2018, Journal of Mathematical Biology.

[46]  J. Sobel,et al.  Pre-symptomatic transmission of pandemic influenza H1N1 2009: investigation of a family cluster, Brazil , 2012, Epidemiology and Infection.

[47]  Yoshiaki Gu,et al.  Pandemic (H1N1) 2009 Transmission during Presymptomatic Phase, Japan , 2011, Emerging infectious diseases.

[48]  Qin Li,et al.  Infectivity of Severe Acute Respiratory Syndrome during Its Incubation Period , 2009, Biomedical and Environmental Sciences.

[49]  Pejman Rohani,et al.  Appropriate Models for the Management of Infectious Diseases , 2005, PLoS medicine.

[50]  J. C. López-Marcos An upwind scheme for a nonlinear hyperbolic integro-differential equation with integral boundary condition , 1991 .